A Phase 1/2 Study of the Oral RET Inhibitor LOXO-292 in Pediatric Patients with Advanced RET-Altered Solid or Primary Central Nervous System Tumors

oxo Oncology, Inc.0 个研究点目标入组 90 人开始时间: 2019年6月11日最近更新: 2020年5月11日

适应症

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方
入组人数: 90

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•1. Pediatric patients = 6 months of age and = 21 years of age at Cycle 1 Day 1 (C1D1) with a locally advanced or metastatic solid or primary CNS tumor that has relapsed, progressed or was nonresponsive to available therapies and/or for which no standard or available systemic curative therapy exists.
•a) Patients with locally advanced disease who would require, in the option of the Investigator, disfiguring surgery or limb amputation to achieve a complete surgical resection are also eligible.
•2. Evidence of an activating RET gene alteration in tumor and/or blood is required as identified through molecular assays, as performed for clinical evaluation.
•3. Patients with primary CNS tumors or cerebral metastasis:
•a) Must be neurologically stable based on stable neurologic exam for 7 days prior to enrollment
•b) Must have not required increasing doses of steroids within the 7 days prior to study entry to manage CNS symptoms
•4. Imaging study must be performed within 28 days of C1D1 while on stable dose steroid medication (if needed) for at least 7 days immediately before the imaging study.
•5. Histologic verification of malignancy at original diagnosis or relapse, except in patients with intrinsic brain stem tumors, optic pathway gliomas, or patients with pineal tumors and elevations of cerebral spinal fluid (CSF) or serum tumor markers including alpha-fetoprotein or beta-human chorionic gonadotropin (HCG).
•6. Patients must have measurable or evaluable disease.
•7. Karnofsky (patients 16 years and older) or Lansky (patients younger than 16 years) performance score of at least 50.
•8. Patients must have fully recovered from the acute toxic effects of all prior anti-cancer chemotherapy to CTCAE (v5.0) Grade = 2.
•9. An archival (FFPE or fresh frozen) or fresh tumor tissue sample must be available (refer to Section 7.5 of the protocol).
•10. Adequate hematologic status, defined as:
•a) Absolute neutrophil count (ANC) = 0.75× 10^9/L not requiring growth factor support for at least 7 days prior to treatment unless evidence of disease involvement in the bone marrow.
•b) Platelet count = 75 × 10^9/L not requiring transfusion support for at least 7 days prior to treatment unless evidence of disease involvement in the bone marrow.
•c) Hemoglobin (Hb) = 8 mg/dL not requiring transfusion support or erythropoietin for at least 7 days prior to treatment unless evidence of disease involvement in the bone marrow.
•11. Adequate hepatic function, defined as:
•a) Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) = 2.5 × the upper limit of normal (ULN) or = 5 × ULN with documented liver involvement (such as liver metastasis or a primary biliary tumor) and
•b) Total bilirubin = 1.5 × ULN or = 3 × ULN with documented liver involvement (patients with Gilbert’s Disease may be enrolled with prior Sponsor approval).
•12. Adequate renal function, defined as:
•a) Estimated glomerular filtration rate = 30 mL/min/1.73 m2 based on local institutional practice for determination, or a minimum serum creatinine by age and gender as presented in Synopsis Table 3.
•13. Ability to comply with outpatient treatment, laboratory monitoring, and required clinic visits for the duration of study participation.
•14. Willingness of male and female patients with reproductive potential to utilize double effective birth control methods
•15. Ability to swallow capsules, liquid suspension, or gastric access via a naso- or gastric tube.
•16. Parent/guardian of child or adolescent patient has th

排除标准

•1. Major surgery within 14 days (2 weeks) prior to C1D1.
•2. Clinically significant active cardiovascular disease or history of myocardial infarction within 6 months prior to C1D1; ongoing cardiomyopathy; or current prolonged QT interval corrected for heart rate (QTc) interval > 470 milliseconds.
•3. Active uncontrolled systemic bacterial, viral, or fungal infection, which in the opinion of the Investigator makes the risk: benefit ratio for the patient to participate in the trial unfavorable.
•4. Clinically significant active malabsorption syndrome or other condition likely to affect gastrointestinal absorption of the study drug.
•5. Pregnancy or lactation.
•6. Uncontrolled symptomatic hyperthyroidism or hypothyroidism (i.e. the patient required a modification to current thyroid medication in the 7 days prior to first dose of study treatment).
•7. Uncontrolled symptomatic hypercalcemia or hypocalcemia.
•8. Current treatment with strong cytochrome P450 3A4 (CYP3A4) inhibitors or inducers (refer to Appendix D of the main protocol for examples).
•9. Known hypersensitivity to any of the components of the investigational agent, LOXO-292 or Ora-Sweet® SF and OraPlus®, for patients who will receive LOXO-292 suspension.
•10. Current treatment with proton pump inhibitors (PPIs).

研究者

发起方

oxo Oncology, Inc.

相似试验

进行中（未招募）

1 期

A Phase 1/2 Study on the effects of the LOXO-292 (study drug) in Pediatric Patients with Advanced Solid or Primary Central Nervous System Tumors

CTIS2023-507703-63-00oxo Oncology Inc.90

招募中

1 期

A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) TumorsAdvanced RET-Altered Solid or Primary Central Nervous System Tumors

JPRN-jRCT2080225127Eli Lilly and Company / ICCC :Medpace Japan KK100

进行中（未招募）

1 期

A Phase 1/2 Study on the effects of the LOXO-292 (study drug) in Pediatric Patients with Advanced Solid or Primary Central Nervous System TumorsPediatric Patients with Advanced RET-Altered Solid or Primary Central Nervous System TumorsMedDRA version: 21.0Level: PTClassification code 10007958Term: Central nervous system neoplasmSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10007959Term: Central nervous system neoplasm NOSSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10049516Term: Malignant tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.1Level: HLTClassification code 10007960Term: Central nervous system neoplasms malignant NECSystem Organ Class: 100000004852MedDRA version: 21.1Level: PTClassification code 10027105Term: Medullary thyroid cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2019-000212-28-FRoxo Oncology, Inc., a wholly owned subsidiary of Eli Lilly and Company90

进行中（未招募）

1 期

EUCTR2019-000212-28-DEoxo Oncology, Inc., a wholly owned subsidiary of Eli Lilly and Company90

进行中（未招募）

1 期

A Phase 1/2 Study on the effects of the LOXO-292 (study drug) in Pediatric Patients with Advanced Solid or Primary Central Nervous System Tumors

EUCTR2019-000212-28-ITOXO ONCOLOGY INCORPORATED90